Current Report Filing (8-k)
December 15 2017 - 7:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): December 14, 2017
NEKTAR
THERAPEUTICS
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
0-24006
|
|
94-3134940
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
455
Mission Bay Boulevard South
San
Francisco, California 94158
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (415) 482-5300
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02
Termination of a Material Definitive Agreement
On November 24, 2017,
Nektar Therapeutics, a Delaware corporation (the “Company”) reported on a Form 8-K that it did not expect Bayer Healthcare
LLC (“Bayer”) to continue further development of Amikacin Inhale.
On
December
14, 2017, the Company received formal notice of termination from Bayer of the Co-Development, License and Co-Promotion Agreement,
dated August 1, 2007, between the Company and Bayer, effective as of January 13, 2018 (“Agreement”). There are
no payment obligations to Bayer that arise as a result of the termination of the Agreement, and the Company will avoid incurring
approximately $25 to $30 million in commercial manufacturing scale-up and readiness costs over the next 12-18 months that would
have been required to meet the Company’s obligations under the Agreement. Please refer to the Company's Current Report on
Form 8-K filed with the Securities and Exchange Commission on August 6, 2007, for a full description of the Agreement.
SIGNATURES
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
|
By:
|
/s/
Mark A. Wilson
|
|
|
Mark
A. Wilson
General Counsel and Secretary
|
|
|
|
|
Date:
|
December
15, 2017
|
|
|
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Sep 2023 to Sep 2024